SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (NCT04775082)
🩺 Plain-English Summary (8th-Grade Level)
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (5 items).
Location: TMC Hlthcr Clin Res Office — Tucson, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- A self-reported (or by parent(s)/LAR (legally acceptable representative) where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records
- Treatment with any medication for the indication of obesity within the past 90 days before screening
- Type 1 diabetes
- Subjects with secondary causes of obesity (for example hypothalamic, monogenic or endocrine causes)
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (32 Sites)
- TMC Hlthcr Clin Res Office — Tucson, Arizona
- Children's Hospital Colorado — Denver, Colorado
- Solaris Clinical Research — Meridian, Idaho
- Pennington Biom Res Ctr — Baton Rouge, Louisiana
- Barry J. Reiner, MD LLC — Baltimore, Maryland
- University of Minnesota_CPOM — Minneapolis, Minnesota
- UBMD Peds-Div of Endo/Diabetes — Buffalo, New York
- PriMed Clinical Research — Dayton, Ohio
- UPMC Child Hosp-Pittsburgh — Pittsburgh, Pennsylvania
- UZ Brussel — Brussels,
- UZ Leuven - Kindergeneeskunde — Leuven,
- Endolife Specialty Hospitals — Guntur, Andhra Pradesh
- Mamc & Lnjp — New Delhi,
- Rambam MC - Department of Pediatrics A — Haifa,
- Schneider MC - Endrocrinology and Diabetes — Petah Tikva,
- University Malaya Medical Centre — Lembah Pantai, Kuala Lumpur
- Hospital Putrajaya — Putrajaya,
- Consultorio de Endocrinología y Pediatría — Puebla City,
- Hospital da Luz Lisboa, S.A. — Lisbon,
- Hospital da Luz — Lisbon,
- Centro Hospitalar Lisboa Norte — Lisbon,
- Unidade De Santa Maria E.P.E. - Hospital de Santa Maria — Lisbon,
- ULS De Santo António, E.P.E. - Hospital de Santo António — Porto,
- Unidade Local de Saúde de Santo António, E.P.E — Porto,
- CUF-Porto — Porto,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.